2. Pancancer Paradigm Advances
Our top highlight for 2018 was the debut of the first site-agnostic or pancancer therapy designed to treat cancer with specific characteristics regardless of where it occurs. That trend continued in 2019. In August, the Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of tumors anywhere in the body that carry genetic alterations known as TRK fusions, as well as for metastatic non-small-cell lung cancer with ROS1 gene fusions. Several other pancancer therapies are in the pipeline, including next-generation TRK inhibitors and two drugs that target RET fusions or mutations, BLU-667 and selpercatinib.
